Biogen Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Biogen Inc 公司

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Biogen Inc簡介



公司代碼BIIB

公司名稱Biogen Inc

上市日期Sep 17, 1991

CEOViehbacher (Christopher A)

員工數量7605

證券類型Ordinary Share

年結日Sep 17

公司地址225 Binney Street

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02142

電話17814642000

網址https://www.biogen.com/

公司代碼BIIB

上市日期Sep 17, 1991

CEOViehbacher (Christopher A)

Biogen Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

61.89K

+8.95%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+10.82%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

22.10K

+20.79%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

19.61K

+27.48%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

16.08K

+30.17%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+19.19%

Mr. Jesus B. Mantas

Independent Director

8.42K

+28.15%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

8.04K

+12.73%

Dr. Adam James Keeney, Ph.D.

Executive Vice President, Head of Corporate Development

5.88K

+59.46%

Dr. Maria C. Freire, Ph.D.

Independent Director

5.47K

+43.29%

名稱

名稱/職務

職務

持股

持股變動

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

61.89K

+8.95%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+10.82%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

22.10K

+20.79%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

19.61K

+27.48%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

16.08K

+30.17%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+19.19%

收入明細

單位: USD更新時間: 4月6日週一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Spinal Muscular Atrophy-SPINRAZA

2.15B

21.78%

MS product revenues-TYSABRI

1.67B

16.84%

MS product revenues-Fumarate

1.43B

14.42%

MS product revenues-Interferon

945.60M

9.56%

Biosimilar product revenues-BENEPALI

453.20M

4.58%

其他

3.25B

32.82%

地區USD

名稱

營收

佔比

United States

3.73B

37.67%

Rest of world

3.57B

36.11%

United states-Revenues from anti-CD20 therapeutic

1.86B

18.81%

Rest of World-Other revenues

732.90M

7.41%

業務

地區

業務USD

名稱

營收

佔比

Spinal Muscular Atrophy-SPINRAZA

2.15B

21.78%

MS product revenues-TYSABRI

1.67B

16.84%

MS product revenues-Fumarate

1.43B

14.42%

MS product revenues-Interferon

945.60M

9.56%

Biosimilar product revenues-BENEPALI

453.20M

4.58%

其他

3.25B

32.82%

股東統計

更新時間: 15 小時前

持股股東

股東類型

持股股東

佔比

PRIMECAP Management Company

10.00%

Vanguard Capital Management, LLC

6.46%

BlackRock Institutional Trust Company, N.A.

5.91%

Fidelity Management & Research Company LLC

5.40%

State Street Investment Management (US)

4.85%

其他

67.39%

持股股東

佔比

PRIMECAP Management Company

10.00%

Vanguard Capital Management, LLC

6.46%

BlackRock Institutional Trust Company, N.A.

5.91%

Fidelity Management & Research Company LLC

5.40%

State Street Investment Management (US)

4.85%

其他

67.39%

股東類型

持股股東

佔比

Investment Advisor

66.96%

Investment Advisor/Hedge Fund

25.97%

Hedge Fund

6.52%

Pension Fund

3.17%

Research Firm

2.81%

Sovereign Wealth Fund

1.84%

Bank and Trust

1.76%

Individual Investor

0.20%

Family Office

0.16%

機構持股



更新時間: 4月9日週四

報告期間

機構數

持股數

持股佔比

持股變動

2026Q1

2085

144.76M

98.05%

-3.98M

2025Q4

1994

139.65M

97.81%

+140.37K

2025Q3

2054

139.52M

98.56%

+3.73M

2025Q2

2076

135.78M

99.30%

-133.40K

2025Q1

2125

136.05M

101.20%

-12.08M

2024Q4

2114

138.28M

98.83%

+2.02M

2024Q3

2089

135.94M

98.13%

+100.43K

2024Q2

2100

135.44M

97.85%

-355.51K

2024Q1

2106

135.99M

97.60%

-5.88M

2023Q4

2136

135.17M

94.89%

+4.09M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

PRIMECAP Management Company

14.76M

10.06%

-196.70K

-1.32%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

8.73M

5.95%

+513.30K

+6.25%

Dec 31, 2025

Fidelity Management & Research Company LLC

7.97M

5.43%

+6.90M

+642.96%

Dec 31, 2025

State Street Investment Management (US)

7.16M

4.88%

-160.73K

-2.20%

Dec 31, 2025

Geode Capital Management, L.L.C.

4.20M

2.86%

+130.62K

+3.21%

Dec 31, 2025

Wellington Management Company, LLP

3.55M

2.42%

-695.24K

-16.37%

Dec 31, 2025

Point72 Asset Management, L.P.

2.81M

1.92%

-1.06M

-27.36%

Dec 31, 2025

Norges Bank Investment Management (NBIM)

2.64M

1.8%

+374.66K

+16.55%

Dec 31, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Invesco Biotechnology & Genome ETF

5.49%

First Trust NASDAQ Pharmaceuticals ETF

4.45%

iShares Neuroscience and Healthcare ETF

4.25%

First Trust NYSE Arca Biotechnology Index Fund

3.53%

VanEck Biotech ETF

3.46%

Invesco Pharmaceuticals ETF

3.01%

iShares Health Innovation Active ETF

2.81%

First Trust Health Care Alphadex Fund

2.4%

ProShares Ultra Nasdaq Biotechnology

2.22%

Alger Russell Innovation ETF

2.21%

Invesco Biotechnology & Genome ETF

佔比5.49%

First Trust NASDAQ Pharmaceuticals ETF

佔比4.45%

iShares Neuroscience and Healthcare ETF

佔比4.25%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.53%

VanEck Biotech ETF

佔比3.46%

Invesco Pharmaceuticals ETF

佔比3.01%

iShares Health Innovation Active ETF

佔比2.81%

First Trust Health Care Alphadex Fund

佔比2.4%

ProShares Ultra Nasdaq Biotechnology

佔比2.22%

Alger Russell Innovation ETF

佔比2.21%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據